PharmaTelevision - Karin Bryskhe, CEO of Colloidal Resource tells us how they can help Pharma Companies save time and money in the preclinical phase

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Karin Bryskhe, CEO of Colloidal Resource tells us how they can help Pharma Companies save time and money in the preclinical phase

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Karin Bryskhe, CEO of Colloidal Resource

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Colloidal Resource: Expertise in Colloidal science

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston, in September 2011. On this show I have Karin Bryskhe , who is the CEO of a company called Colloidal Resource which is based in Lund in Sweden, welcome to the show.

Karin Bryskhe:

Thank you very much.

Fintan Walton:

Karin, Colloidal Resource as I said is based in Lund it has many operations, but one of the its operations as a company called CR Competence which deals in the area of science of colloidal science and research and we are here to talk about that CR Competence, but first of all my first question to you is what does CR Competence do?

Karin Bryskhe:

Yes, we are experts in colloidal science and colloidal science explains the interactions and structures in for example emulsions, dispersions, solutions and else these systems can typically be pharmaceutical formulations like drug delivery vehicles, and liposomes and even gel suspension that could be used for topical formulations.

Fintan Walton:

Okay, so how did you get into this particular field is that something that your own background is and how did you develop your expertise in Colloidal science?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Karin Bryskhe

CEO

Karin Bryskhe presently serves as CEO of Colloidal Resource.Karin Bryskhe has been an entrepreneur since she ended her "around the world trip" in 1993. Now she has the position as CEO in two companies. In 2005 she founded her third company, Colloidal Resource a consultant business based at the chemical centre in Lund. In 2008 she won the Innovation Prize together with co-workers for an innovative way to use MR scanners without contrast fluids. For the same innovation she won the Venture cup business plan competition which has resulted in the resent founded company CR development. Karin Bryskhe graduated from Lund University and has a PhD in Physical Chemistry. Her thesis Formation of Block Copolymer and Surfactant Vesicles was founded on theoretical work as well as extensive laboratory work including techniques such as dynamic light scattering, NMR diffusion and cryo-transmission electron microscopy. She has a number of scientific publications and was recently nominated for the female entrepreneur award in Sweden.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Colloidal Resource

Colloidal Resource began in late summer 2005. Karin Bryskhe and Anna Stenstam was then recently qualified from the Division of Physical Chemistry 1 at Lund University, a department with the best reputation, both nationally and internationally. During the years of chemistry center, they had had experience of working with the latest technology in both traditional chemistry and in recent years the high-profile nano-chemistry. It was clear to both of them to the basis of chemistry are solutions to many problems as responsible for not only research but particularly product development is facing. Moreover, with a good plan is often only a few confirmatory tests and in academia are several tools that may be more useful. The possibility that the good relations with Lund University to work with the research community as a base - for companies with real product was the founding Colloidal Resource and the two subsidiaries. CR Development was born from the same environment - the actual presence of the chemical center. Together with Professor Daniel Topgaard, former graduate student colleague of Anna and Karin applied for patents on the technology, Daniel worked with. The possibility of Daniel's technology, previously used in yeast cells, could differentiate the different types of cancer laid the foundation for OncoPulse and the first subsidiary.